Bumper Offer - Urjas oil Just @ Rs. 1
Orabliss 2%/2% Gel is a prescription drug, available for use as Gel. Local Anesthesia, Nutritional Deficiency are some of its major therapeutic uses. The alternative uses of Orabliss 2%/2% Gel have also been explained below.
The optimal dosage of Orabliss 2%/2% Gel is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
Common side effects of Orabliss 2%/2% Gel include Skin redness. Apart from the aforementioned side effects, Orabliss 2%/2% Gel can also lead to other problems, which have been listed below. Usually, these side effects of Orabliss 2%/2% Gel go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Orabliss 2%/2% Gel is Moderate for pregnant women and Moderate for women who are breastfeeding. Warnings related to Orabliss 2%/2% Gel's effects on the liver, heart and kidney, if any, have been listed below.
Orabliss 2%/2% Gel can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Orabliss 2%/2% Gel in conditions like Heart Failure, Liver Disease. Some other conditions that can be affected by Orabliss 2%/2% Gel are listed in the contraindications section below.
Besides this, Orabliss 2%/2% Gel may also have severe interaction with some medicines. A complete list of these interactions is given below.
You should also be aware that Orabliss 2%/2% Gel is safe while driving, and is addiction.
Orabliss 2%/2% Gel is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Based on research, the following side effects have been observed when Orabliss 2%/2% Gel is used -
Severe
Moderate
Mild
Common
Is the use of Orabliss 2%/2% Gel safe for pregnant women?
Orabliss Gel can cause unwanted side effects in pregnant women. If you experience any side effects, stop taking Orabliss Gel right away. Take your doctor's advice before taking it again.
Is the use of Orabliss 2%/2% Gel safe during breastfeeding?
Orabliss Gel may lead to some side effects in breastfeeding women. If you witness any unusal symptoms after taking Orabliss Gel, discontinue its use and call your doctor right away. Follow your doctor's advice regarding the use of Orabliss Gel.
What is the effect of Orabliss 2%/2% Gel on the Kidneys?
Very few cases of side effects of Orabliss Gel on kidney have been reported.
What is the effect of Orabliss 2%/2% Gel on the Liver?
Very few cases of side effects of Orabliss Gel on the liver have been reported.
What is the effect of Orabliss 2%/2% Gel on the Heart?
Side effects of Orabliss Gel rarely affect the heart.
Orabliss 2%/2% Gel should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Orabliss 2%/2% Gel unless your doctor advises you to do so -
Is this Orabliss 2%/2% Gel habit forming or addictive?
No, you will not get addicted to Orabliss 2%/2% Gel.
Interaction between Food and Orabliss 2%/2% Gel
Due to the absence of research, it is difficult to say how Orabliss 2%/2% Gel and food will interact.
Interaction between Alcohol and Orabliss 2%/2% Gel
It is difficult to say anything about the effect of Orabliss 2%/2% Gel and alcohol. No research has been done on this yet.
Yes, Orabliss Gel may cause drowsiness or sleepiness. It is a common side effect of this drug. Activities such as driving and operating heavy machinery should be avoided after taking this Orabliss Gel to prevent accidents and injuries as it causes drowsiness.
Orabliss Gel is a local anesthetic which is used to cause numbness and block pain. It is safe as long as one uses it under the medical supervision, however, if misused or overused, it can cause serious side effects such as seizure, slow breathing, severe burning, and irritation. Therefore, one must follow the instructions of a doctor completely while using Orabliss Gel.
No, Orabliss Gel is not a narcotic. It is a local anesthetic agent which is used to cause numbness and block pain. Narcotics are the natural products like opium and its derivatives, heroin, coca leaf, and cannabis, synthetic drugs like pethidine, methadone, codeine, and morphine. These are also prescription drugs and must be taken cautiously as these can cause an addiction.
According to an FDA warning published in 2014, a 2% solution of Orabliss Gel should not be used in infants and young children (5 months to 3.5 years old), as too much application of Orabliss Gel or accidental swallowing may cause serious brain injury, seizures, and heart problems. Therefore, for treating teething pain, one must take the advice of their doctor and follow his recommendations completely.
Yes, Orabliss Gel may cause an allergic reaction which might manifest as sneezing, wheezing, pruritis (severe itching of the skin), urticaria (localized swollen itchy area), episodes of angioneurotic edema (swelling of the lower layer of skin or mucous membranes and even anaphylactic shock (very severe allergic reaction). If you develop any of these symptoms while using Orabliss Gel, please inform your doctor immediately.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xylocaine (lidocaine HCl)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 366
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 771-775